Background: Remimazolam is a new benzodiazepine of sedative drugs with an ultra-short-acting anesthetic effect, being commonly used for critically ill patients (especially septic patients) in intensive care units (ICUs). Although some anesthetics have been reported to show certain anti-inflammatory effects, the role of remimazolam in inflammation is still remained unknown.Methods: In the present study, LPS-induced endotoxemia mice were used to observe the effect of remimazolam in vivo.

more »

... lated bone marrow cells and Raw 264.7 cells were used to evaluate the influence of remimazolam on macrophage in vitro.Results: Compared with LPS treatment group, remimazolam remarkably improved survival rate of endotoxemia mice and decreased the release of LPS-induced inflammatory mediators, such as TNF-a, IL-6 and IL-1b. Remimazolam not only inhibited the activation of MyD88 and PI3K signal pathway at 15min after LPS treatment but also disturb Rab5a related TLR4 expression at cell surface in response to LPS at later time.Conclusions: Remimazolam inhibit LPS‑induced inflammatory responses of macrophages and obviously improve the survival rate of endotoxemia mice.